Caerulein treatment of Parkinson's disease

G. Bruno, S. Ruggieri, T. N. Chase, K. Bakker, C. A. Tamminga

Research output: Contribution to journalArticle

1 Scopus citations

Abstract

In view of evidence linking cholecystokinin-containing neurons with both dopamine system function and Parkinson's disease pathophysiology, the therapeutic effects of the cholecystokinin analog, caerulein, were evaluated in 10 parkinsonian patients stabilized on L-Dopa therapy. Despite substantially elevated plasma caerulein levels immediately following intramuscular injection of this peptide, no consistent change in neurologic status could be discerned. These negative results may be due to the relatively small amounts of caerulein entering the CNS at dose levels that do not induce gastrointestinal toxicity.

Original languageEnglish (US)
Pages (from-to)266-270
Number of pages5
JournalClinical Neuropharmacology
Volume8
Issue number3
Publication statusPublished - 1985

    Fingerprint

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Clinical Neurology
  • Neuroscience(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Bruno, G., Ruggieri, S., Chase, T. N., Bakker, K., & Tamminga, C. A. (1985). Caerulein treatment of Parkinson's disease. Clinical Neuropharmacology, 8(3), 266-270.